Clinical trials

Semaglutide Results Timeline: What Trial Data Shows Week by Week

A week-by-week map of what happened in the semaglutide trials — when appetite changes, when the scale moves, when side effects peak, and when weight loss levels off.

Last verified September 14, 2026·13 sources cited

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Search for “semaglutide results week by week” and you will find dozens of charts promising exactly how many pounds you should lose by week 4, week 8 and week 12. Almost none of them come from trial data, because the trials did not report weight that way. They reported endpoints at week 68 or week 104, with a curve in between.

What the trials do support is a picture of the shape of the process: when the dose changes, when side effects cluster, when the scale starts moving in earnest, and when it stops. That is what this page maps out.

Two ground rules before starting. First, none of this is a dosing schedule or a target — dose decisions belong to a prescriber, and the FDA-approved labeling is the authority on how these products are used. Second, every number here is a group average from a clinical trial. Individual results in the trials varied enormously.

Weeks 1 to 4: what does the starting dose actually do?

In the STEP trials, semaglutide was started at a low dose and stepped up roughly every four weeks over a 16-week escalation period before reaching the full maintenance dose [1]. That escalation exists for one reason: to reduce nausea and vomiting. The starting dose is not intended to produce weight loss.

This is the single biggest mismatch between expectations and the trial data. People often start counting results from week one, but during the first month trial participants were still on a fraction of the dose that eventually produced the published outcomes.

What people typically report in this window is a change in appetite — feeling full sooner, thinking about food less — often before the scale reflects much. The trials did not systematically measure “food noise,” but appetite suppression is the drug’s established mechanism.

Side effects also concentrate here and at each subsequent step up. In STEP 1, nausea and diarrhea were the most common adverse events and the authors described them as “typically transient and mild-to-moderate in severity” that “subsided with time” [1].

Weeks 5 to 16: what happens while the dose is climbing?

Each escalation step tends to bring a fresh wave of gastrointestinal symptoms that then settles. Across the program, gastrointestinal adverse events were reported by 74% of participants on semaglutide 2.4 mg in one trial and 82-84% in others, versus 34-63% on placebo — high numbers, but overwhelmingly mild to moderate events rather than serious ones.

Discontinuation in this window is where trial data and real-world data diverge sharply. In STEP 1, only 4.5% of participants stopped because of gastrointestinal events [1]. In an academic obesity clinic cohort, 14% had discontinued by three months. In the Cleveland Clinic real-world study, people who stopped within three months lost only 3.6% of their body weight at one year, versus 11.9% among those who kept going [2].

Weight is coming off during this period, but the curve is still shallow. The full dose has not been reached for most of it.

Week 20: what is the clearest early data point?

STEP 4 gives the best-documented milestone anywhere in the semaglutide literature, because the trial was designed around it. All 803 participants took semaglutide for a 20-week run-in before being randomized to continue or switch to placebo. At the end of that run-in, mean weight loss was 10.6% of body weight [3].

That is roughly five months, and roughly 24 pounds for someone starting at 235 pounds — a meaningful early result, and a useful reality check in both directions. It is far more than a typical diet produces in five months. It is also well short of the 14.9% headline from STEP 1, which took another 48 weeks to reach.

Weeks 20 to 52: when does the weight come off fastest?

This is where most of the remaining weight comes off. Participants are on the full maintenance dose, gastrointestinal symptoms have generally settled for those who stayed on, and the curve is at its steepest.

The trials did not publish clean weekly weights, but the endpoints bracket the range. STEP 1 ended at 68 weeks with -14.9% [1]. STEP 4’s continuing-treatment arm went from -10.6% at week 20 to about -17.4% total by week 68 [3]. Working backward, the bulk of the additional loss in both trials occurred between roughly week 20 and week 60.

For anyone tracking their own numbers: this is the period where a monthly weigh-in shows the most movement, and where the difference between staying at a full dose and drifting to a lower one shows up most clearly in the data.

Weeks 52 to 68: what happens as the curve flattens?

The curve starts to flatten. In STEP 1 the weight trajectory was clearly decelerating by the end of the 68-week trial.

This is also where the trial-versus-real-world gap becomes visible. Trial participants had scheduled visits, free drug and a research team. Real-world one-year weight loss averaged 8.7% across 7,881 patients in the Cleveland Clinic cohort, with 80.8% never having reached a high maintenance dose. Among those who did reach a high dose and stayed on it, one-year weight loss was 13.7% — close to the trial figure [2].

Year 2 and beyond: does the plateau hold?

Two datasets answer what happens after the first year.

STEP 5 ran 104 weeks in 304 adults. Weight change at two years was -15.2% versus -2.6% on placebo [4]. Compare that with STEP 1’s -14.9% at 68 weeks: the second year added almost nothing on average, but it also did not reverse.

SELECT is the long view. The prespecified weight analysis of all 17,604 participants showed weight loss continuing for about 65 weeks and then holding steady through week 208 — four full years [5]. At the end, mean reduction was 10.2% versus 1.5% on placebo, with waist circumference down 7.7 cm.

So the shape is: down for roughly 15 months, then flat for as long as the data goes. A plateau is the expected outcome of the process working, not a sign that the drug has stopped working. Weight regain while still taking the drug is a different thing and worth mentioning to a healthcare provider.

It is worth noting that SELECT’s 10.2% is lower than STEP 1’s 14.9%. That reflects a different population — older, with established heart disease — less intensive lifestyle support, and an analysis that includes everyone regardless of whether they stayed on treatment.

What happens if you stop at any point in this timeline?

The curve runs in reverse.

In STEP 4, participants switched to placebo at week 20 gained 6.9% of body weight over the following 48 weeks, while those who continued lost a further 7.9% [3]. The regain was a steady climb, not a sudden rebound.

In the STEP 1 extension, 327 participants were followed for a year after both the drug and the lifestyle intervention were stopped at week 68. They regained 11.6 percentage points of the 17.3% they had lost — about two-thirds — ending at 5.6% below their original starting weight [6]. Blood pressure, cholesterol and blood sugar improvements largely reverted toward baseline over the same period.

This is the most important thing the timeline shows: the plateau holds only while treatment continues.

Where do the higher doses and the pill fit on this timeline?

Semaglutide 7.2 mg (Wegovy HD). The STEP UP trial ran 72 weeks and reported -18.7% versus -15.6% for 2.4 mg and -3.9% for placebo [7]. The FDA’s March 2026 approval specifies the higher dose for people who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated [8]. In practice that puts the step up to 7.2 mg well after the standard escalation, not as part of it. Side effects were more frequent at the higher dose, including dysesthesia — unusual skin sensations — reported by 22.9% versus 6.0% at 2.4 mg [7].

Oral semaglutide 25 mg (Wegovy tablet). OASIS 4 ran 71 weeks with co-primary endpoints at week 64 and reported -13.6% versus -2.2% on placebo [9]. The tablet is supplied in escalating strengths of 1.5 mg, 4 mg, 9 mg and 25 mg, so it has its own titration path. The overall timeline shape — escalate, then a long steady decline, then a plateau — looks similar.

Semaglutide in type 2 diabetes. STEP 2 ran the same 68 weeks at the same 2.4 mg dose in people with type 2 diabetes and reached -9.6% [10]. The shape of the curve is similar; the magnitude is smaller.

What can you reasonably expect in the first six months?

Pulling the evidence together, rather than inventing weekly targets:

Month 1: mostly titration. Appetite changes are commonly reported; scale movement is usually modest. Gastrointestinal side effects are most likely now and after each dose step.
Months 2 to 4: continued escalation toward the maintenance dose, with weight coming off at an accelerating rate. This is also when most real-world discontinuation happens.
Month 5 (around week 20): the STEP 4 run-in benchmark of about 10.6% average loss.
Month 6 onward: the steepest part of the curve, if the full dose has been reached and tolerated.
Around month 15: the plateau, in both STEP 1 and SELECT.
Years 2 to 4: essentially flat on continued treatment, per STEP 5 and SELECT.

Individual variation around all of this is large. In STEP 1, half of participants lost 15% or more and roughly one in seven did not reach 5% [1]. In STEP 8, 38.5% of semaglutide participants lost 20% or more [11]. No published analysis identifies a dependable way to predict where a given person lands.

When is a stall worth asking about?

A flattening curve after roughly a year matches the trial data and is expected.

Things that are worth raising with a healthcare provider rather than working out alone: weight regain while still on a stable dose; side effects that are not settling after a dose step; difficulty getting to or staying at a maintenance dose; or any symptom that concerns you. Those are dose and clinical questions, and there are real reasons a prescriber may want to look at them — including interactions with other medications, thyroid or gallbladder issues, and conditions the labels flag.

What the trials cannot tell you is what will happen in your body over the next 12 months. What they can tell you is the shape of the road, and that most of the distance is covered in the middle of the first year rather than at the start.

Sources

Questions people ask

When does semaglutide start working?

The appetite effect begins within the first weeks, but the starting dose is deliberately low and is used for tolerability rather than effect. In the STEP trials it took about 16 weeks to reach the full maintenance dose, and weight loss accumulated steadily over the whole 68 weeks rather than arriving quickly.

How much weight should I have lost after 4 weeks?

No trial reports a week-4 target, and the starting dose is a titration step rather than a therapeutic dose. Some people notice reduced appetite in the first month while the scale has barely moved. Setting a four-week weight goal is not something the trial data supports.

What happened by 20 weeks in the trials?

The STEP 4 trial included a 20-week run-in on semaglutide before randomization. Participants had lost an average of 10.6% of body weight by that point, which is the cleanest 20-week data point available.

When does weight loss plateau on semaglutide?

In STEP 1 the curve flattened toward the end of the 68-week trial. In SELECT, which ran four years, weight loss continued for about 65 weeks and then held steady through week 208. A plateau after roughly 15 months is the expected pattern, not a sign of failure.

When are side effects worst?

Across the trials, gastrointestinal events were most common during dose escalation and generally eased over time. In STEP 1 the authors described nausea and diarrhea as typically transient, mild to moderate, and subsiding with time.

Does weight loss keep going after a year?

Only a little. STEP 1 reported 14.9% at 68 weeks and STEP 5 reported 15.2% at 104 weeks — essentially flat over the second year. SELECT showed the same plateau holding for four years.

How long does it take to reach the full dose?

The STEP trials used a 16-week escalation, stepping up roughly every four weeks. The FDA approval of the 7.2 mg dose specifies that people should have tolerated 2.4 mg for at least four weeks first. Actual dosing decisions belong to a prescriber.

What if my weight loss stalls at month 3?

Trial curves are group averages and individual weeks are noisy. A plateau late in the first year matches what the trials found. A stall earlier than that is worth raising with a healthcare provider, who can look at dose, timing and other medications.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.